ALS

MedTech

Synchron's brain-computer interface hits one-year safety mark

One year after placement of Synchron's Stentrode implant, no study participants have experienced any adverse events that led to disability or death.
Andrea Park Mar 31, 2022 10:40am

Orphazyme on last legs amid restructuring, more layoffs

Mar 10, 2022 6:24pm

Maze snares $190M as its top asset aims for clinic

Jan 10, 2022 7:30am

After FDA U-turn, Amylyx heads for IPO to support ALS drug

Dec 17, 2021 10:45am

ALS organizations call on Senate to pass $500M neuro R&D bill

Dec 9, 2021 4:00pm

Denali makes ALS play, hustling Sanofi-allied drug into phase 2 

Oct 7, 2021 7:35am